GlassScriptPhysician profile
Carolina Hernandez
NPI 1851146757
$7,074.18
in general payments reported to CMS, 2019-2025
21 companies · $4,587 in 2025
The $4,587 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,487 · 2025: $4,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,836 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,836.19 |
| Education | $237.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,134.21 | 2024-2025 | Evenity, Enbrel, Otezla |
| Abbvie INC. | $1,021.68 | 2024-2025 | |
| Ucb, INC. | $806.58 | 2024-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $754.93 | 2024-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $654.35 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $607.07 | 2024-2025 | |
| Janssen Biotech, INC. | $532.05 | 2024-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $271.75 | 2024-2025 | |
| Radius Health, INC. | $236.37 | 2024-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $223.35 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Aurinia Pharma U.S., INC. | $217.61 | 2024-2025 | Lupkynis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $118.85 | 2025 | Benlysta |
| Genzyme Corporation | $79.69 | 2025 | |
| Genentech USA, INC. | $76.46 | 2025 | Ocrevus Zunovo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65.36 | 2024 | Taltz |
| Sobi, INC | $45.45 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $33.63 | 2025 | Orencia |
| Octapharma USA, INC. | $29.13 | 2024 | Octagam Immune Globulin (Human) |
| Fresenius Kabi USA, LLC | $24.17 | 2024 | Idacio |
| Kiniksa Pharmaceuticals International, Plc | $16.50 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolina Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.